2022 Speakers

"Perfect balance of both academic and industry viewpoints on leveraging CRISPR technology"

Previous CRISPR 2.0 Event Series Attendee

Aditya Raguram

PhD Student

David Liu Lab, Harvard University

Alexandra Crawley

Co-Founder & Senior Scientist

LifeEDIT

Amy Simon

Chief Medical Officer

Beam Therapeutics

Brett Staahl

Co-Founder & VP Platform

Scribe Therapeutics

Carlo Zambonelli

Senior Director – Analytical Sciences

Beam Therapeutics

CB Gurumurthy

Professor

University of Nebraska Medical School

Darren Hart

Senior Vice President, Development

Graphite Bio

David Guay

Vice President Innovation and Technology

Feldan Therapeutics

Eric B. Kmiec

Executive Director & Chief Scientific Officer

ChristianaCare Gene Editing Institute

Erik Willems

Senior Manager, Cell Biology R&D

Thermo Fisher Scientific

Glen Gowers

Co-Founder

Basecamp Research

Guillaume Pavlovic

Head of Genetic Engineering and Model Validation Department

Institut Clinique De La Souris

Howard Wu

Founder & Chief Scientific Officer

Full Circles Therapeutics

Inge Yung-Chih Cheng

Principal Scientist

Pfizer

Ira Gotliv

Vice President – Preclinical Research

Emendo Biotherapeutics

Jeremy Duffield

Chief Scientific Officer

Prime Medicine

John Murphy

Chief Scientific Officer

Arbor Biotechnologies

Jonathan Yen

Director of Therapeutic Genome Engineering

St. Jude Children’s Research Hospital

Kiran Musunuru

Professor of Medicine Director

Perelman School of Medicine, University of Pennsylvania

Lin Wu

Director, Genome Modification Facility

Harvard University

Liron Walsh

Head of Development; In Vivo Programs

Intellia Therapeutics

Max Sellman

Product Manager, Gene Editing

Aldevron

Michael Maitland

Senior Director, Clinical Development

Intellia Therapeutics

Paul Donohoue

Senior Scientist – Platform Discovery Group Lead

Caribou Biosciences

Rafi Emmanuel

Senior Vice President - Research & Development

Emendo Biotherapeutics

Rammohan Devulapally

Principal Scientist – Drug Delivery Chemistry and Nanoparticle Formulation Development

GenEdit

Rebecca Nugent

Vice President, Platform Research

Synthego

Roberto Nitsch

Associate Director

AstraZeneca

Samuel Du

MD-PhD Student

Krzysztof Palczewski Lab, University of California Irvine

Sunghwa Choe

Chief Executive Officer

G+Flas Life Science

Terence Ta

Associate Director

Prime Medicine

Thomas Mullen

Chief Scientific Officer

SeQure Dx

Weston Miller

Vice President - Clinical Development

Graphite Bio